Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Rajkumar

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
Blood Cancer Journal|August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupJ Hillengass, L A Moulopoulos, S Delorme, et al.
Heart (British Cardiac Society)|January 10, 2014
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosisA Dispenzieri, M A Gertz, S K Kumar, et al.
Leukemia|May 24, 2016
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Blood Cancer Journal|May 2, 2015
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathR Warsame, S K Kumar, M A Gertz, et al.
Leukemia|January 25, 2008
Genetic aberrations and survival in plasma cell leukemiaR E Tiedemann, N Gonzalez-Paz, R A Kyle, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
Blood Cancer Journal|August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupJ Hillengass, L A Moulopoulos, S Delorme, et al.
Heart (British Cardiac Society)|January 10, 2014
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosisA Dispenzieri, M A Gertz, S K Kumar, et al.
Leukemia|May 24, 2016
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Blood Cancer Journal|May 2, 2015
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathR Warsame, S K Kumar, M A Gertz, et al.
Leukemia|January 25, 2008
Genetic aberrations and survival in plasma cell leukemiaR E Tiedemann, N Gonzalez-Paz, R A Kyle, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Pageof 17